AR108712A1 - (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis - Google Patents

(5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis

Info

Publication number
AR108712A1
AR108712A1 ARP170101596A ARP170101596A AR108712A1 AR 108712 A1 AR108712 A1 AR 108712A1 AR P170101596 A ARP170101596 A AR P170101596A AR P170101596 A ARP170101596 A AR P170101596A AR 108712 A1 AR108712 A1 AR 108712A1
Authority
AR
Argentina
Prior art keywords
methyl
propil
metoxi
diona
imidazolidin
Prior art date
Application number
ARP170101596A
Other languages
English (en)
Original Assignee
Galapagos Nv
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Servier Lab filed Critical Galapagos Nv
Publication of AR108712A1 publication Critical patent/AR108712A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), o una sal farmacéuticamente aceptable, o un solvato, o una sal farmacéuticamente aceptable de un solvato del mismo; o un metabolito biológicamente activo del mismo.
ARP170101596A 2016-06-09 2017-06-09 (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis AR108712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1610055.4A GB201610055D0 (en) 2016-06-09 2016-06-09 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis

Publications (1)

Publication Number Publication Date
AR108712A1 true AR108712A1 (es) 2018-09-19

Family

ID=56894696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101596A AR108712A1 (es) 2016-06-09 2017-06-09 (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis

Country Status (6)

Country Link
US (1) US10829478B2 (es)
EP (1) EP3468955B1 (es)
AR (1) AR108712A1 (es)
GB (1) GB201610055D0 (es)
TW (1) TW201802079A (es)
WO (2) WO2017211666A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041407A4 (en) * 2019-10-07 2023-10-25 D.E. Shaw Research, LLC ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKING CHANNEL BLOCKERS
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
CN113754635A (zh) * 2020-06-02 2021-12-07 成都康弘药业集团股份有限公司 稠环类化合物及其制备方法和用途
WO2022007866A1 (zh) * 2020-07-09 2022-01-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380236T3 (es) * 2005-10-28 2012-05-09 Takeda Pharmaceutical Company Limited Compuesto de amida heterocíclica y uso del mismo
PT2650310T (pt) 2012-04-13 2016-09-01 Rottapharm Biotech Srl Anticorpo anti-adamts-5, derivados e utilizações dos mesmos
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
JO3501B1 (ar) * 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)

Also Published As

Publication number Publication date
EP3468955B1 (en) 2021-01-06
US10829478B2 (en) 2020-11-10
EP3468955A1 (en) 2019-04-17
WO2017211666A1 (en) 2017-12-14
TW201802079A (zh) 2018-01-16
US20190315719A1 (en) 2019-10-17
GB201610055D0 (en) 2016-07-27
WO2017211668A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
AR108712A1 (es) (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA201891489A1 (ru) Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант
PH12018500061A1 (en) Oxysterols and methods of use thereof
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
EP4316591A3 (en) Oxysterols and methods of use thereof
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
AR103680A1 (es) Inhibidores selectivos de bace1
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA202092620A1 (ru) Соли и твердые формы монобактамного антибиотика
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
AR110770A1 (es) Moduladores del canal de potasio
WO2015001541A3 (en) Pharmaceutical film composition
EA201890616A1 (ru) Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов

Legal Events

Date Code Title Description
FB Suspension of granting procedure